Login
Home
Charts
Search
Watchlist
Products

Goldline Pharmaceutical Ltd

GLPL·BSE
₹33.310.00%Mon, 21 Sept '26
Industry:Trading
Indices:

Goldline Pharmaceutical Ltd

GLPL
BSE
₹33.31
0.00%
|Mon, 21 Sept '26
SOICxStockScans Reports
Industry
Trading
Indices
View
Financials
Documents
Shareholdings
Corporate Actions
Segments
Quick Ratios
Quarterly Results
Profit & Loss
Balance Sheet
Cash Flow
Ratios
Peer Comparison
Financials
Documents
Shareholdings
Corporate Actions
Segments
Quick Ratios
Quarterly Results
Profit & Loss
Balance Sheet
Cash Flow
Ratios
Peer Comparison
6M
Price
Charts
Documents

Quick Ratios

Edit Ratios
Mkt Cap
Market Capitalization
₹32Cr
Close
Close Price
₹33.31
Industry
Industry
Trading
PE
Price To Earnings
—
PS
Price To Sales
1.02
Revenue
Revenue
₹31Cr
Rev Gr TTM
Revenue Growth TTM
—
PAT Gr TTM
PAT Growth TTM
—

Quarterly Results

Standalone
Numbers
Percentage
QuarterSep 2025Mar 2026
Revenue
RevenueCr
1417
Growth YoY
Revenue Growth YoY%
Expenses
ExpensesCr
1113
Operating Profit
Operating ProfitCr
34
OPM
OPM%
18.924.9
Other Income
Other IncomeCr
00
Interest Expense
Interest ExpenseCr
11
Depreciation
DepreciationCr
00
PBT
PBTCr
24
Tax
TaxCr
01
PAT
PATCr
13
Growth YoY
PAT Growth YoY%
NPM
NPM%
9.815.9
EPS
EPS₹
0.00.0
QuarterSep 2025Mar 2026
Revenue
RevenueCr
1417
Growth YoY
Revenue Growth YoY%
Expenses
ExpensesCr
1113
Operating Profit
Operating ProfitCr
34
OPM
OPM%
18.924.9
Other Income
Other IncomeCr
00
Interest Expense
Interest ExpenseCr
11
Depreciation
DepreciationCr
00
PBT
PBTCr
24
Tax
TaxCr
01
PAT
PATCr
13
Growth YoY
PAT Growth YoY%
NPM
NPM%
9.815.9
EPS
EPS₹
0.00.0

Profit & Loss

Standalone
Numbers
Percentage
Financial YearMar 2023Mar 2024Mar 2025Mar 2026
Revenue
RevenueCr
20242831
Growth
Revenue Growth%
18.719.111.2
Expenses
ExpensesCr
18192224
Operating Profit
Operating ProfitCr
2467
OPM
OPM%
11.118.320.822.3
Other Income
Other IncomeCr
0000
Interest Expense
Interest ExpenseCr
2221
Depreciation
DepreciationCr
0000
PBT
PBTCr
0345
Tax
TaxCr
0111
PAT
PATCr
0234
Growth
PAT Growth%
603.856.945.3
NPM
NPM%
1.37.710.113.2
EPS
EPS₹
0.43.04.16.0
Financial YearMar 2023Mar 2024Mar 2025Mar 2026
Revenue
RevenueCr
20242831
Growth
Revenue Growth%
18.719.111.2
Expenses
ExpensesCr
18192224
Operating Profit
Operating ProfitCr
2467
OPM
OPM%
11.118.320.822.3
Other Income
Other IncomeCr
0000
Interest Expense
Interest ExpenseCr
2221
Depreciation
DepreciationCr
0000
PBT
PBTCr
0345
Tax
TaxCr
0111
PAT
PATCr
0234
Growth
PAT Growth%
603.856.945.3
NPM
NPM%
1.37.710.113.2
EPS
EPS₹
0.43.04.16.0

Balance Sheet

Standalone
Numbers
Percentage
Financial YearMar 2023Mar 2024Mar 2025Mar 2026
Equity Capital
Equity CapitalCr
2277
Reserves
ReservesCr
2426
Current Liabilities
Current LiabilitiesCr
9101212
Non Current Liabilities
Non Current LiabilitiesCr
5543
Total Liabilities
Total LiabilitiesCr
19232629
Current Assets
Current AssetsCr
17202326
Non Current Assets
Non Current AssetsCr
3333
Total Assets
Total AssetsCr
19232629
Financial YearMar 2023Mar 2024Mar 2025Mar 2026
Equity Capital
Equity CapitalCr
2277
Reserves
ReservesCr
2426
Current Liabilities
Current LiabilitiesCr
9101212
Non Current Liabilities
Non Current LiabilitiesCr
5543
Total Liabilities
Total LiabilitiesCr
19232629
Current Assets
Current AssetsCr
17202326
Non Current Assets
Non Current AssetsCr
3333
Total Assets
Total AssetsCr
19232629

Cash Flow

Standalone
Financial YearMar 2023Mar 2024Mar 2025Mar 2026
Operating Cash Flow
Operating Cash FlowCr
2333
Investing Cash Flow
Investing Cash FlowCr
-1-100
Financing Cash Flow
Financing Cash FlowCr
-1-1-3-3
Net Cash Flow
Net Cash FlowCr
010-1
Free Cash Flow
Free Cash FlowCr
1233
CFO To PAT
CFO To PAT%
931.9161.8112.268.4
CFO To EBITDA
CFO To EBITDA%
109.067.954.540.6
Financial YearMar 2023Mar 2024Mar 2025Mar 2026
Operating Cash Flow
Operating Cash FlowCr
2333
Investing Cash Flow
Investing Cash FlowCr
-1-100
Financing Cash Flow
Financing Cash FlowCr
-1-1-3-3
Net Cash Flow
Net Cash FlowCr
010-1
Free Cash Flow
Free Cash FlowCr
1233
CFO To PAT
CFO To PAT%
931.9161.8112.268.4
CFO To EBITDA
CFO To EBITDA%
109.067.954.540.6

Ratios

Standalone
Financial YearMar 2023Mar 2024Mar 2025Mar 2026Current
Valuation Ratios
Valuation Ratios
Market Cap
Market CapitalizationCr
32
Price To Earnings
Price To Earnings
Price To Sales
Price To Sales
1.0
Price To Book
Price To Book
1.3
EV To EBITDA
EV To EBITDA
Profitability Ratios
Profitability Ratios
GPM
GPM%
70.674.261.564.164.1
OPM
OPM%
11.118.320.822.322.3
NPM
NPM%
1.37.710.113.213.2
ROCE
ROCE%
13.524.128.531.031.0
ROE
ROE%
6.329.833.233.133.1
ROA
ROA%
1.37.910.814.314.3
Operational Ratios
Operational Ratios
Solvency Ratios
Solvency Ratios
Liquidity Ratios
Liquidity Ratios
Financial YearMar 2023Mar 2024Mar 2025Mar 2026Current
Valuation Ratios
Valuation Ratios
Market Cap
Market CapitalizationCr
32
Price To Earnings
Price To Earnings
Price To Sales
Price To Sales
1.0
Price To Book
Price To Book
1.3
EV To EBITDA
EV To EBITDA
Profitability Ratios
Profitability Ratios
GPM
GPM%
70.674.261.564.164.1
OPM
OPM%
11.118.320.822.322.3
NPM
NPM%
1.37.710.113.213.2
ROCE
ROCE%
13.524.128.531.031.0
ROE
ROE%
6.329.833.233.133.1
ROA
ROA%
1.37.910.814.314.3
Operational Ratios
Operational Ratios
Solvency Ratios
Solvency Ratios
Liquidity Ratios
Liquidity Ratios

Documents — Goldline Pharmaceutical Ltd

  • Q4 FY2026 Quarterly Result (Mar 2026, PDF): https://www.stockscans.in/document/08piq2ipts6licrxvpgysy83.pdf
  • FY2026 Annual Report (PDF): https://www.stockscans.in/document/kozz5g23r839wve0ss3hup9f.pdf

Simplify stock analysis with powerful tools and clear insights for confident, data-driven decisions.

support@stockscans.in
© StockScans by SOIC Technologies Pvt Ltd
349 A, Lodhi Road, Punjabi Bazar, New DelhiData provided by CMOTS Internet Technologies